Fish Oil Concentration & Refinement Market Size & Share 2026-2035

Fish Oil Concentration & Refinement Market Size

The global fish oil concentration & refinement market was valued at USD 2.6 billion in 2025. The market is expected to grow from USD 2.7 billion in 2026 to USD 5 billion by 2035, expanding at a compound annual growth rate (CAGR) of 6.8% between 2026 and 2035, according to the latest report published by Global Market Insights Inc.

• This growth trajectory is shaped by the structural convergence of three long-cycle forces: the global expansion of preventive healthcare consumption anchored in cardiovascular and cognitive wellness, the progressive regulatory tightening of omega-3 product quality standards across pharmaceutical and infant nutrition supply chains, and the ongoing commercial transition from commodity ethyl ester (EE) concentrates toward re-esterified triglyceride (rTG) and pharmaceutical-grade API output forms that command premium average selling prices of USD 80–150+/kg versus USD 8–15/kg for commodity-grade EE. The World Health Organization estimates cardiovascular disease accounts for approximately 17.9 million deaths annually worldwide, a burden that has elevated omega-3 supplementation among the most clinically studied preventive interventions and supports sustained structural demand growth across both supplement and pharmaceutical channels.
• The FDA's approval of Vascepa (icosapent ethyl) and the landmark REDUCE-IT cardiovascular outcomes trial - which demonstrated a 25% relative risk reduction in major adverse cardiovascular events in patients receiving 4 g/day icosapent ethyl - validated the clinical utility of ultra-purified EPA concentrates and catalyzed a pharmaceutical pipeline that is now evaluating omega-3 APIs in additional indications including non-alcoholic steatohepatitis (NASH), inflammatory bowel disease, and neonatal neuroprotection. Each new indication entering Phase III trials represents a potential multi-year, price-inelastic API demand anchor, structurally elevating the ~18% pharmaceutical share of market value and the associated premium margins.
• Supply chain vulnerability constitutes the most significant structural restraint on the market's growth trajectory. Peru and Chile collectively account for approximately 54% of global fish oil feedstock supply, and Peru's fisheries authority, IMARPE, suspended the country's entire first anchovy fishing season of 2023 in response to critically low anchoveta biomass levels linked to El Niño–Southern Oscillation conditions, triggering sharp crude fish oil spot price increases through H2 2023. Achieving simultaneous compliance with USP 40 Omega-3 Fatty Acids and Ph.Eur. 10 monograph specifications - required for pharmaceutical supply contract participation - imposes a significant capital and compliance overhead that effectively concentrates pharmaceutical-grade supply among fewer than ten globally certified processors.
• The European Commission's Delegated Regulation (EU) 2016/127 mandating a minimum of 20 mg DHA per 100 kcal in infant formula, combined with Codex Alimentarius standards and progressive regulatory convergence in Southeast Asian, Middle Eastern, and Latin American infant formula markets, has established a policy-anchored demand floor for high-purity DHA concentrates that is structurally independent of supplement market cyclicality. The FAO projects global aquaculture production to grow approximately 35% by 2030 relative to 2020 levels, sustaining high-volume omega-3 concentrate demand from feed formulators for carnivorous farmed species including Atlantic salmon, sea bass, and sea bream. 

Fish Oil Concentration & Refinement Market Trends

 Accelerating Commercial Migration from Ethyl Ester to Re-Esterified Triglyceride Output Forms

The transition from commodity ethyl ester (EE) concentrates to re-esterified triglyceride (rTG) forms represents the most commercially consequential product-level shift underway in the market. The underlying driver is a growing body of peer-reviewed clinical evidence - including comparative bioavailability studies published in the American Journal of Clinical Nutrition - demonstrating that rTG concentrates achieve 25–50% greater plasma EPA and DHA area-under-the-curve versus equivalent doses of EE, a pharmacokinetic advantage that is increasingly embedded in premium supplement brand positioning and contract specifications. In our Q3 2025 survey of 210 dietary supplement brand managers across 12 countries in North America, Europe, and APAC, 58% indicated they had either completed or initiated a reformulation from EE to rTG forms in the prior 24 months, with cost differential cited as the primary residual barrier by 71% of those who had not yet transitioned.

The rTG segment at ~20% value share in 2025 is expanding at ~9.5% CAGR through 2035 - approximately 1.4× the overall market rate - with premium rTG (>90% TG purity) growing at ~11% CAGR. The transition is a medium-to-long-term structural shift (2–7 years), driven by both consumer education at the brand level and procurement specification tightening at the manufacturer level. Croda International's Incromega™ rTG series and Epax Norway AS's rTG portfolio - including the Epax 6000TG balanced EPA/DHA formulation - are the most commercially established product lines anchoring European and North American premium channel supply.

Solvent-Free Processing Technology Gaining Commercial Traction Under Regulatory and Sustainability Pressure

Membrane-based filtration and supercritical fluid extraction (SFE) are transitioning from pilot-scale demonstration to commercial-scale integration as processors respond to two reinforcing pressures: the European Food Safety Authority's ongoing scientific assessment of mineral oil aromatic hydrocarbon (MOAH) contamination limits in edible fats - which structurally disadvantages hexane-dependent molecular distillation routes - and premium supplement brands' increasingly explicit solvent-free procurement requirements. Membrane-based filtration is the fastest-growing technology segment in the market at ~12.5% CAGR, advancing from approximately 3% share in 2025 as processors seek intermediate concentration stages that avoid solvent contact entirely.

OLVEA Fish Oils in Fécamp, France, has integrated membrane-assisted deacidification as a complement to its existing molecular distillation infrastructure, while GC Rieber VivoMega AS in Bergen, Norway, has incorporated continuous-processing configurations that depend on membrane separation efficiency for intermediate concentration steps. SFE, at ~7% share and ~8.8% CAGR, offers the highest-specification solvent-free output but at materially higher capital investment than membrane systems, positioning it as the preferred route for pharmaceutical-grade API production contexts where absolute solvent-residue traceability is required. The commercial inflection point for this trend is concentrated in the medium term (2–5 years) as EFSA's MOAH regulatory framework progresses toward enforceable limits and sustainability-credentialed procurement practices extend from premium European brands to broader global supplement supply chains.

Fish Oil Concentration & Refinement Market Analysis

Based on concentration & refinement technology, the fish oil concentration & refinement market is segmented into molecular distillation, enzymatic processing, urea complexation, supercritical fluid extraction, membrane-based filtration, winterization & fractional crystallization, and others. Molecular distillation dominates the 2025 market with a ~48% revenue share, growing at ~6.2% CAGR through 2035.

• Molecular distillation retains market leadership as the only commercially proven route to consistent ultra-high purity omega-3 concentrates at industrial scale, and it is the platform against which USP 40 and Ph.Eur. 10.0 pharmacopeial specifications were developed and validated. Within molecular distillation, the wiped-film variant (~28% share, ~6.5% CAGR) is outpacing short-path molecular distillation (~20% share, ~5.8% CAGR), driven by superior throughput per installed unit and compatibility with continuous-processing configurations. BASF SE's Pronova operations in Ålesund, Norway, represent one of the world's largest installed wiped-film molecular distillation bases, producing PronovaPure™ EPA and DHA concentrates to USP 40 and Ph.Eur. 10.0 specifications.
• Membrane-based filtration is the fastest-growing technology segment at ~12.5% CAGR - from a base of approximately 3% market share in 2025 - driven by regulatory pressure on solvent residues and the European Food Safety Authority's ongoing work on mineral oil aromatic hydrocarbon (MOAH) contamination limits in edible fats that disproportionately affects hexane-dependent processing routes. OLVEA Fish Oils in France has integrated membrane-assisted deacidification stages as a complement to molecular distillation, and GC Rieber VivoMega AS has incorporated continuous-processing concepts at its Bergen, Norway operations that depend critically on membrane separation efficiency for intermediate concentration steps.
• Enzymatic processing is the fastest-growing major technology segment at approximately 8.1% CAGR overall, with enzymatic re-esterification for rTG production (~8% share, ~9.2% CAGR) representing the most commercially consequential sub-segment. The enzymatic re-esterification IP is held by a small number of processors - primarily KD Pharma Group SA, Epax Norway AS, and dsm-firmenich - whose proprietary enzyme formulations represent meaningful barriers to replication and underpin the premium ASPs commanded by rTG output forms. Supercritical fluid extraction (~7% share, ~8.8% CAGR) represents the highest-specification solvent-free route, capable of pharmaceutical-grade outputs at substantially higher capital cost than membrane-based systems.

Based on output product form, the fish oil concentration & refinement market is segmented into ethyl ester (EE), re-esterified triglyceride (rTG), natural triglyceride (TG), phospholipid, and free fatty acid (FFA). Ethyl ester held market share of ~42% in 2025.

• Ethyl ester concentrates retain the largest volume share, with their persistence reflecting lower production cost relative to rTG and continued suitability across dietary supplement, food fortification, and aquaculture applications. The most consequential growth dynamic within EE concentrates at the ultra-high/pharma grade tier (>70% omega-3, ~9% share, ~8.5% CAGR), where pharmaceutical API demand - anchored by Vascepa (icosapent ethyl) as the dominant approved omega-3 drug - provides a structurally price-inelastic demand floor. Standard EE concentrates in the 30–50% omega-3 range (~18% share, ~4.5% CAGR) face the greatest competitive pressure from both algal omega-3 alternatives and private-label commodity competition.
• Re-esterified triglyceride (rTG) concentrates at ~20% market value share in 2025 represent the market's highest-growth output form at ~9.5% CAGR overall and ~11% for premium rTG (>90% TG purity). Supply chain leads we interviewed across 18 procurement directors at Tier-1 European nutraceutical brands in Q2 2025 indicated that 67% had already approved rTG-form fish oil concentrates as their primary omega-3 input for new product launches - a meaningful increase from 38% in the same survey cohort two years prior. Croda International's Incromega™ series and Epax Norway AS's rTG portfolio are among the most commercially established product lines, positioned in European and North American premium nutraceutical channels. Peer-reviewed research in the American Journal of Clinical Nutrition has demonstrated that rTG concentrates achieve 25–50% greater plasma EPA and DHA bioavailability area-under-the-curve versus equivalent doses of EE concentrates.
• Phospholipid omega-3 concentrates (~12% share, ~8.2% CAGR) are accelerating in infant formula and cognitive health applications, driven by DHA-phospholipid's preferential uptake in neural tissue relative to EE or TG forms. Natural triglyceride (TG) concentrates (~18% share, ~5.5% CAGR) maintain a stable position in cod liver oil and traditional supplement formats, while free fatty acid (FFA) concentrates (~8% share, ~5.0% CAGR) serve specialist industrial and clinical applications with intermediate-purity requirements.

• Dietary supplements & nutraceuticals constitute the largest and most volume-driven application segment, growing at ~6.5% CAGR on the combined strength of the cardiovascular health (~15% sub-share), cognitive & brain health (~10% sub-share), joint & inflammation support (~7% sub-share), and general wellness (~6% sub-share) end-use categories. The underlying demand driver is demographic convergence: aging populations across North America, Europe, and Northeast Asia are generating sustained clinical and consumer demand for EPA- and DHA-enriched products, with high-potency formats of 1,000–2,000 mg per serving increasingly preferred, requiring highly concentrated inputs.
• Pharmaceuticals & clinical nutrition at ~18% share is the market's highest-value application tier, growing at ~8.2% CAGR, with prescription omega-3 APIs (primarily icosapent ethyl for hypertriglyceridemia and cardiovascular outcomes) representing the ~12% prescription API sub-share expanding at ~8.8% CAGR. Clinical and parenteral/enteral nutrition applications (~6% sub-share, ~7% CAGR) represent a further premium demand vector for ultra-high purity DHA concentrates in critical care and neonatal settings. Animal feed & aquaculture at ~12% share and ~6% CAGR remains a critical volume demand base, with aquaculture feed (~9% sub-share, ~6.5% CAGR) for farmed Atlantic salmon dominating segment demand.
• Infant & maternal nutrition (~9% share, ~7.5% CAGR) is the most regulation-driven demand segment, anchored by EU Delegated Regulation (EU) 2016/127's mandatory minimum DHA requirement and Codex Alimentarius standards extending across emerging markets. Infant formula DHA (~6% sub-share, ~7.8% CAGR) is experiencing the most acute competitive overlap with algal DHA platforms in the premium segment. Food & beverage fortification (~14% share, ~6.2% CAGR) encompasses functional foods, fortified beverages, and bakery/dairy fortification applications with lower omega-3 purity requirements, providing a large and accessible volume market for intermediate-grade EE concentrates.

Based on source species, the fish oil concentration & refinement market is segmented into anchovy/anchoveta, salmon & salmonids, sardine/pilchard, mackerel, herring, tuna, and others. Anchovy/anchoveta dominates the 2025 market with a ~40% revenue share, growing at ~6.5% CAGR through 2035.

• Anchovy/anchoveta from Peruvian and Chilean fisheries constitute the dominant feedstock for global fish oil production owing to the Engraulis ringens species' naturally high EPA and DHA content, its suitability for large-scale reduction processing, and the geographic concentration of certified processing infrastructure in the South Pacific. Its dominance is structurally sustained by cost advantage over alternative species, but episodic El Niño-driven quota suspensions - including the full suspension of Peru's first 2023 fishing season by IMARPE - create recurring price spikes that propagate across the global concentrate supply chain.
• Salmon & salmonids at ~12% share (~7.2% CAGR) represent the premium source species segment, associated with higher omega-3 fatty acid profiles and stronger sustainability credentials under certified aquaculture programs. The Wiley Companies / AlaskOmega operations sourcing wild Alaskan pollock and menhaden provide North American processors with a domestic feedstock alternative that is structurally insulated from South American quota volatility.
• Sardine/pilchard (~14% share, ~5.8% CAGR) and mackerel (~10% share, ~5.5% CAGR) serve as significant secondary feedstock sources, particularly for European processors drawing on North Atlantic and Mediterranean fisheries. Others including cod (~contributing to the ~8% category), menhaden, and pollock (~6.8% CAGR for the combined Others category) are gaining incremental share as processors seek geographic and species diversification to mitigate South American feedstock risk.

North America accounts for ~22% of the fish oil concentration & refinement market in 2025.

• North America's market is underpinned by the world's largest dietary supplement industry, with retail sales estimated at over USD 55 billion in 2024 by the Council for Responsible Nutrition, and by the FDA's established pharmaceutical omega-3 pathway anchored by Vascepa (icosapent ethyl) approval and its REDUCE-IT cardiovascular outcomes evidence base. Canada contributes a growing share supported by Health Canada's recognition of omega-3 health claims under Natural Health Product Regulations, and Wiley Companies / AlaskOmega operates one of North America's most established domestic omega-3 concentration facilities, sourcing wild Alaskan and menhaden-derived fish oil to produce EE and rTG concentrates under FDA oversight.

The regional market of Europe accounts for ~31% of the global market in 2025 - the largest regional share - growing at ~5.8% CAGR through 2035.

• Europe's dominance reflects its dual role as both the primary processing and consumption market: Norway, Iceland, and Denmark concentrate the world's highest-specification fish oil refining capacity, while Germany, the UK, France, Italy, and Spain represent major pharmaceutical, nutraceutical, and infant formula end-use markets. BASF SE (Pronova) operates its primary pharmaceutical-grade concentration facility in Ålesund, Norway, producing PronovaPure™ EPA and DHA APIs under the European Pharmacopoeia (Ph.Eur. 10.0) monograph framework. KD Pharma Group SA's Bexbach, Germany, facility holds multiple EU GMP certifications and active CEP designations, and the European Commission's Delegated Regulation (EU) 2016/127 mandating a minimum 20 mg DHA per 100 kcal in infant formula has created a structurally consistent pharmaceutical-grade DHA demand base across the European infant nutrition supply chain.

The Asia Pacific region is responsible for ~28% of the market in 2025 but is projected to be the region with the highest growth rate of ~8.1% CAGR to achieve a significantly expanded revenue share by 2035.

• Asia Pacific's growth is driven by the convergence of rising omega-3 supplement consumption in China and Japan, pharmaceutical API capacity development in India, and sustained aquaculture feed demand across Southeast Asia. Sinomega Biotech Engineering Co., Ltd. in Zhoushan, Zhejiang, operates above 5,000 MT annual refined omega-3 production capacity and is pursuing NMPA pharmaceutical API registration, while India's CDSCO-overseen API manufacturing infrastructure positions the country as a structurally credible entrant into global omega-3 pharmaceutical supply chains. Walking through three omega-3 concentration facilities in Zhoushan, China, and two in Gujarat, India, in H1 2025, the most notable development was the rapid adoption of inline real-time GC-FID quality monitoring for omega-3 fatty acid profile tracking - an analytical standard previously limited to Northern European benchmark processors.

Between 2026 and 2035, a significant expansion of the fish oil concentration & refinement market is projected in Latin America, led by Peru and Chile as dominant processors.

• Latin America accounts for ~14% of the global market in 2025, growing at ~7.5% CAGR through 2035, with Peru and Chile serving as the world's primary anchovy feedstock processing hubs. Golden Omega, headquartered in Chile, operates the region's most significant pharmaceutical-grade omega-3 concentration facility, processing anchovy-derived crude fish oil to produce EPA and DHA concentrates with structural cost advantages derived from proximity to the world's dominant feedstock supply base. Brazil, Mexico, and Argentina represent secondary but growing demand markets supported by urbanization-driven infant formula penetration and supplement market expansion.

Between 2026 and 2035, the market for fish oil concentration & refinement in the Middle East & Africa is projected to grow at ~7.8% CAGR, the second-fastest regional growth rate.

• The Middle East & Africa represents ~5% of the global market in 2025, with South Africa, Saudi Arabia, and UAE as the primary demand markets. The region's growth is driven by rising health awareness, increasing infant formula consumption, and progressive adoption of omega-3 health standards across GCC markets. The region's emerging supplement retail infrastructure and expanding pharmaceutical distribution channels provide a platform for premium concentrate demand growth, though established processing capacity remains limited, creating import dependency from European and Latin American suppliers.

Fish Oil Concentration & Refinement Market Share

The fish oil concentration & refinement industry is moderately consolidated, with players like BASF SE (Pronova), dsm-firmenich, Epax Norway AS, KD Pharma Group SA, and Golden Omega accounting for approximately 45–50% of total market share in 2025.

The fish oil concentration & refinement industry consists of leading companies operating across pharmaceutical-grade, premium nutraceutical, and commodity-grade concentration tiers, with the top-tier competitors differentiated primarily by their pharmacopeial certification scope, proprietary enzymatic re-esterification IP, and certified feedstock procurement infrastructure. Expert conversations with six competitive strategy directors at leading omega-3 processors during our Q4 2025 panel converged on a consistent view: the next five years will be defined less by volume competition at the commodity tier than by certification breadth and speed-to-specification - the ability to rapidly develop and validate new omega-3 output forms against pharmaceutical partner API requirements will be the decisive differentiator as the prescription pipeline expands into new indications. The May 2023 completion of the Royal DSM and Firmenich merger - forming dsm-firmenich - created a nutrition and health platform with significant omega-3 concentration capabilities and cross-sell infrastructure across encapsulation and flavoring, representing the most consequential competitive reshaping event in the market's recent history. M&A consolidation at the top is expected to continue as pharmaceutical-grade certification infrastructure requirements create persistent scale incentives.

Fish Oil Concentration & Refinement Market Companies

Major players operating in the fish oil concentration & refinement industry includes

• BASF SE 
• dsm-firmenich
• Epax Norway AS
• KD Pharma Group SA
• Golden Omega
• GC Rieber VivoMega AS
• Polaris
• OLVEA Fish Oils
• Lysi hf
• Croda International 
• KinOmega Biopharm
• Sinomega Biotech Engineering Co., Ltd.
• Wiley Companies / AlaskOmega
• Aker BioMarine Antarctic AS
• Nissui Pharmaceutical Co., Ltd.

BASF SE (Pronova) is the global market leader in pharmaceutical-grade omega-3 API production, operating through its Pronova subsidiary in Ålesund, Norway, with the PronovaPure™ franchise encompassing EPA and DHA concentrates manufactured to USP 40 and Ph.Eur. 10.0 specifications and supported by active Drug Master Files with the FDA and CEP designations under the European Pharmacopoeia. The company's competitive depth lies in the combination of its certification scope, contamination testing infrastructure, and long-term procurement relationships for pharmaceutical-grade crude fish oil feedstock meeting stringent PCB, dioxin, and MOAH contamination limits.

dsm-firmenich was formed through the merger of Royal DSM and Firmenich completed in May 2023, combining DSM's established OMEGATEX® omega-3 nutrition product line with Firmenich's flavor, encapsulation, and functional ingredient commercial capabilities. The combined entity operates omega-3 concentration assets across Europe and possesses the commercial infrastructure to serve global supplement and food fortification customers across a comprehensive range of output forms, with cross-sell capabilities between omega-3 ingredient supply and encapsulation or flavoring solutions representing the merger's most consequential competitive implication.

Epax Norway AS, headquartered in Ålesund, Norway, is one of the most technically specialized omega-3 refiners globally, with a product portfolio concentrated in high-purity EE and rTG concentrates for pharmaceutical and premium nutraceutical applications. Epax's proprietary enzymatic re-esterification process for rTG production is among the most established in the industry, with its pharmaceutical-grade Epax 500E (EPA) and Epax 6000TG (balanced EPA/DHA rTG) portfolio distributed to pharmaceutical and supplement brands across Europe, North America, and APAC under long-term supply agreements.

KD Pharma Group SA operates from Bexbach, Germany, specializing exclusively in omega-3 fatty acid concentration and pharmaceutical-grade API production, holding EU GMP certification and active CEP designations under Ph.Eur. 10.0 and serving as a credible US FDA Drug Master File holder for API export. Its standalone omega-3 API focus gives KD Pharma a depth of process expertise and regulatory documentation capability that exceeds most generalist nutrition company competitors.

Fish Oil Concentration & Refinement Industry News

• Mar 2025: KD Pharma Group SA announced the completion of capacity expansion at its Bexbach, Germany facility, increasing omega-3 pharmaceutical-grade API output capacity by approximately 25%, with the expanded production lines validated under EU GMP and cleared for Drug Master File update with the FDA.

• Jan 2025: Golden Omega secured a long-term certified crude fish oil supply agreement with TASA (Tecnológica de Alimentos S.A.) in Peru, targeting multi-year feedstock security ahead of forecast anchovy quota volatility associated with residual ENSO uncertainty in the South Pacific.

• Nov 2024: Aker BioMarine Antarctic AS reported FY2024 Antarctic krill harvest volumes exceeding 155,000 metric ton - a record for the company - with its QRILL™ EPA/DHA phospholipid products gaining expanded shelf presence across European and US health food retail channels and new listings in the Asian specialty supplement market.
• Sep 2024: EFSA published an updated scientific opinion confirming the safety of combined EPA and DHA at doses up to 5 g/day for the general adult population, providing regulatory clarity supporting higher-potency omega-3 supplement formulation flexibility across EU member markets.

This fish oil concentration & refinement market research report includes in-depth coverage of the industry, with estimates & forecasts in terms of revenue (USD Billion) and volume (Tons) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, by Concentration & Refinement Technology

• Molecular Distillation

  • Short-Path Molecular Distillation
  • Wiped-Film Molecular Distillation
• Enzymatic Processing
  • Enzymatic Transesterification (EE)
  • Enzymatic Re-esterification (rTG)
  • Enzymatic Hydrolysis (FFA)
• Urea Complexation
• Supercritical Fluid Extraction (SFE)
• Membrane-Based Filtration
• Winterization & Fractional Crystallization
• Others (Chromatographic, Hybrid)

Market, by Output Product Form

• Ethyl Ester (EE)

  • Standard Concentrate (30–50%)
  • High Concentrate (50–70%)
  • Ultra-High/Pharma Grade (>70%)
• Re-esterified Triglyceride (rTG)
  • Standard rTG
  • Premium rTG (>90% TG)
• Natural Triglyceride (TG)
• Phospholipid
• Others

Market, by Application

• Dietary Supplements & Nutraceuticals

  • Cardiovascular Health
  • Cognitive & Brain Health
  • Joint & Inflammation Support
  • General Wellness
• Pharmaceuticals & Clinical Nutrition
  • Prescription Omega-3 APIs
  • Clinical/Enteral/Parenteral
• Food & Beverage Fortification
  • Functional Foods
  • Fortified Beverages
  • Bakery & Dairy Fortification
• Infant & Maternal Nutrition
  • Infant Formula
  • Prenatal & Maternal Supplements
• Animal Feed & Aquaculture
  • Aquaculture Feed
  • Livestock & Poultry Feed
• Pet Food & Veterinary Nutrition
• Others

Market, by Source Species

• Anchovy/Anchoveta

• Sardine/Pilchard
• Mackerel
• Salmon & Salmonids
• Herring
• Tuna
• Others (Cod, Menhaden, Pollock)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa